

To NASDAQ OMX Copenhagen A/S
Translation

Company release No 14/2008

Hørsholm
October 22, 2008

Page 1/2

Persistent vaccination effect of GRAZAX® after completion of treatment

Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX®. For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX®, the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX® persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

During the first year after completion of treatment, GRAZAX® continues to provide statistically significant reductions in both hay fever symptoms and the use of symptom-relieving medication.

In the follow-up year, hay fever symptoms were reduced by 31% while the use of symptom-relieving medication was reduced by 52%. The reduction of symptoms and use of medication is measured as median values relative to a control group in which patients had unrestricted access to symptom-relieving medication.

The patients in the study have adhered to the recommended three-year GRAZAX® treatment regimen and completed treatment in the autumn of 2007. The above-mentioned results cover the 2008 pollen season, the first season in which the patients did not receive active treatment with GRAZAX®.

The fourth-year results represent a major breakthrough, since ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with traditional symptom-relieving allergy medication.

ALK-Abelló A/S

Jens Bager
President and CEO

ALK will host a conference call today at 2.30 p.m. (CET) at which Jens Bager, President and CEO and Executive Vice President of R&D, Henrik Jacobi will review the results. Danish participants must call in on tel +45 7026 5040 before 2.25 p.m. (CET), and international participants must call in on tel +44 208 817 9301 before 2.25 p.m. (CET). The conference call will also be webcast on our website www.alk-abello.com, where the related presentation will be available shortly before the conference call begins.

About ALK

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX[®], was launched in Europe in 2007. ALK has entered into a strategic partnership regarding the tablet programme with Schering-Plough for North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX.com.

For further information please contact:

Jens Bager, President and CEO, tel. +45 4575 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525

Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551